Journal
VIROLOGY
Volume 353, Issue 2, Pages 268-282Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.virol.2006.04.043
Keywords
HIV-1; vaccine; neutralization antibody; consensus inummogens
Categories
Funding
- NIAID NIH HHS [R21AI55386, N01 AI 85338, P0-1, AI061734, P01 AI061734, P01 AI52816, P30 AI051445, P01 AI052816, P01 AI 28147, P01 AI046023, P01 AI028147, R21 AI055386, N01 AI085338-002, P30 AI51445] Funding Source: Medline
Ask authors/readers for more resources
HIV-1 subtype C is the most common HIV-1 group M subtype in Africa and many parts of Asia. However, to date HIV-1 vaccine candidate immunogens have not induced potent and broadly neutralizing antibodies against subtype C primary isolates. We have used a centralized gene strategy to address HIV-1 diversity and generated a group M consensus envelope gene with shortened consensus variable loops (CON-S) for comparative studies with wild-type (WT) Env immunogens. Our results indicate that the consensus HIV-1 group M CON-S Env elicited cross-subtype neutralizing antibodies of similar or greater breadth and titer than the WT Envs tested, indicating the utility of a centralized gene strategy. Our study also shows the feasibility of iterative improvements in Env immunogenicity by rational design of centralized genes. (c) 2006 Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available